retatrutide clinical trial results 2024 2025 press release 🚨 BREAKING: Shows “Bariatric-Level” Weight Loss in Phase 3 New Phase 3 TRIUMPH-1 data show retatrutide may deliver weight-loss outcomes approaching those seen with bariatric surgery—marking one of the most Rusfertide Gains Breakthrough Therapy Designation

The Phase 2 trial used 4-week intervals between increases, and groups that followed dose escalation had better tolerability than those started at fixed higher doses

Using semaglutide in conjunction with a comprehensive nutrition and exercise program, like the Mayo Clinic Diet, is essential

The convenience factor should not be underestimated

[15] [16] [18] Specific probiotic species have been studied for GLP-1 and metabolic support

Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report

The committee's recommendation is non-binding but almost always followed